Cancer Genetics and Epigenetics 2024, Vol.12, No.6, 329-345 http://medscipublisher.com/index.php/cge 341 Chinnaiyan, 2019). Clinical trials investigating the use of ncRNA-based therapies are already underway, highlighting the translational potential of this research (Ferreira and Esteller, 2018; Zhang et al., 2020). However, several challenges must be addressed to fully realize the potential of ncRNAs in personalized medicine. These include the need for robust and reproducible methods for ncRNA detection and quantification, as well as the development of effective delivery systems for ncRNA-based therapeutics (Khan et al., 2021; Pathania, 2023). Additionally, a deeper understanding of the context-dependent roles of ncRNAs in different cancer types and stages is essential for the design of targeted and personalized treatment strategies (Anastasiadou et al., 2017; Wei et al., 2019). While significant progress has been made in understanding the role of ncRNAs in ovarian cancer, several challenges remain. Addressing these research gaps, leveraging technological advances, and exploring the potential of ncRNAs in personalized medicine will be crucial for translating these findings into clinical practice. Continued interdisciplinary efforts and collaboration will be key to overcoming these challenges and unlocking the full potential of ncRNAs in cancer therapy. 10 Concluding Remarks The research on epigenetic regulation mechanisms of non-coding RNAs (ncRNAs) in ovarian cancer (OC) has revealed significant insights into the roles of long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) in the pathogenesis and progression of this malignancy. Key findings include the identification of epigenetically regulated lncRNAs that are associated with clinical outcomes and chemotherapy responses in OC patients. LncRNAs have been shown to act as competitive endogenous RNAs (ceRNAs), influencing OC progression, metastasis, and chemoresistance by interacting with miRNAs and mRNAs. Additionally, the interplay between lncRNAs and the epigenetic machinery, including DNA methylation and histone modifications, has been highlighted as a crucial factor in OC tumorigenesis and therapeutic resistance. Specific lncRNAs, such as RHPN1-AS1 and TTN-AS1, have been identified as key regulators of OC progression through their interactions with miRNAs and signaling pathways.. The findings underscore the potential of lncRNAs as biomarkers for prognosis and therapeutic targets in OC. Future research should focus on further elucidating the molecular mechanisms underlying the epigenetic regulation of lncRNAs and their interactions with other ncRNAs and proteins. Investigating the dynamic regulation of lncRNAs, including their stability and modifications, will provide deeper insights into their roles in OC. Additionally, exploring the therapeutic potential of targeting specific lncRNA-miRNA-mRNA axes, such as the RHPN1-AS1-miR-596-LETM1 and TTN-AS1-miR-139-5p-ROCK2 pathways, could lead to the development of novel treatment strategies. The integration of bioinformatics tools and large-scale sequencing data will be essential for identifying new lncRNAs and understanding their functions in OC. The research on epigenetic regulation mechanisms of ncRNAs in OC has made significant strides, revealing the complex interplay between lncRNAs, miRNAs, and the epigenetic machinery. These findings not only enhance our understanding of OC biology but also open new avenues for the development of precision medicine approaches. By targeting the epigenetic regulation of lncRNAs, it may be possible to improve the diagnosis, treatment, and prognosis of OC patients. Continued research in this field holds promise for uncovering novel biomarkers and therapeutic targets, ultimately leading to better clinical outcomes for those affected by this devastating disease. Acknowledgments Thank you to the peer reviewers for their valuable feedback. Conflict of Interest Disclosure The authors affirm that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==